Topical nepafenac in the treatment of diabetic macular edema

David Callanan, Patrick WilliamsTexas Retina Associates, Arlington, TX, USAPurpose: To determine the safety and efficacy of topical nepafenac 0.1% in the treatment of diabetic macular edema.Methods: A consecutive case series was performed of patients treated with nepafenac monotherapy twice daily fo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	David Callanan, Patrick Williams
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/abae7a7b616b4abd96dbec2d63fb594a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:abae7a7b616b4abd96dbec2d63fb594a
record_format	dspace
spelling	oai:doaj.org-article:abae7a7b616b4abd96dbec2d63fb594a2021-12-02T00:51:06ZTopical nepafenac in the treatment of diabetic macular edema1177-54671177-5483https://doaj.org/article/abae7a7b616b4abd96dbec2d63fb594a2008-10-01T00:00:00Zhttp://www.dovepress.com/topical-nepafenac-in-the-treatment-of-diabetic-macular-edema-a2404https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483David Callanan, Patrick WilliamsTexas Retina Associates, Arlington, TX, USAPurpose: To determine the safety and efficacy of topical nepafenac 0.1% in the treatment of diabetic macular edema.Methods: A consecutive case series was performed of patients treated with nepafenac monotherapy twice daily for diabetic macular edema. Visual acuities (VA) at baseline and final visit were recorded. Foveal thickness, based on optical coherence tomography, was also recorded.Results: Six eyes of 5 patients were included in this study. Median initial Snellen vision was 20/100 (range, 20/40&ndash;20/400). After a mean of 210 days (range, 182&ndash;259), median final VA was 20/75 (range, 20/40&ndash;20/400). Four eyes gained vision and two eyes maintained vision. Mean pre-treatment vision was 0.78 logMAR and final VA was 0.67 logMAR, for a statistically significant improvement (p&nbsp;&lt; 0.05). Mean initial foveal thickness was 417 microns (range, 286&ndash;599). After a mean of 178 days (range, 91&ndash;259), mean foveal thickness was 267 microns (range, 158&ndash;423), showing a statistically significant improvement (p&nbsp;&lt; 0.05). Each eye had an improvement in foveal thickness.Conclusion: The results from these 6 eyes suggest that nepafenac 0.1% may have activity against diabetic macular edema and warrants further investigation.Keywords: diabetes, diabetic macular edema, inflammation, macular edema, nepafenac, NSAIDs David CallananPatrick WilliamsDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2008, Iss Issue 4, Pp 689-692 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 David Callanan Patrick Williams Topical nepafenac in the treatment of diabetic macular edema
description	David Callanan, Patrick WilliamsTexas Retina Associates, Arlington, TX, USAPurpose: To determine the safety and efficacy of topical nepafenac 0.1% in the treatment of diabetic macular edema.Methods: A consecutive case series was performed of patients treated with nepafenac monotherapy twice daily for diabetic macular edema. Visual acuities (VA) at baseline and final visit were recorded. Foveal thickness, based on optical coherence tomography, was also recorded.Results: Six eyes of 5 patients were included in this study. Median initial Snellen vision was 20/100 (range, 20/40&ndash;20/400). After a mean of 210 days (range, 182&ndash;259), median final VA was 20/75 (range, 20/40&ndash;20/400). Four eyes gained vision and two eyes maintained vision. Mean pre-treatment vision was 0.78 logMAR and final VA was 0.67 logMAR, for a statistically significant improvement (p&nbsp;&lt; 0.05). Mean initial foveal thickness was 417 microns (range, 286&ndash;599). After a mean of 178 days (range, 91&ndash;259), mean foveal thickness was 267 microns (range, 158&ndash;423), showing a statistically significant improvement (p&nbsp;&lt; 0.05). Each eye had an improvement in foveal thickness.Conclusion: The results from these 6 eyes suggest that nepafenac 0.1% may have activity against diabetic macular edema and warrants further investigation.Keywords: diabetes, diabetic macular edema, inflammation, macular edema, nepafenac, NSAIDs
format	article
author	David Callanan Patrick Williams
author_facet	David Callanan Patrick Williams
author_sort	David Callanan
title	Topical nepafenac in the treatment of diabetic macular edema
title_short	Topical nepafenac in the treatment of diabetic macular edema
title_full	Topical nepafenac in the treatment of diabetic macular edema
title_fullStr	Topical nepafenac in the treatment of diabetic macular edema
title_full_unstemmed	Topical nepafenac in the treatment of diabetic macular edema
title_sort	topical nepafenac in the treatment of diabetic macular edema
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/abae7a7b616b4abd96dbec2d63fb594a
work_keys_str_mv	AT davidcallanan topicalnepafenacinthetreatmentofdiabeticmacularedema AT patrickwilliams topicalnepafenacinthetreatmentofdiabeticmacularedema
_version_	1718403459833659392

Topical nepafenac in the treatment of diabetic macular edema

Ejemplares similares